Article info
Original article
Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab)
- Correspondence to Dukwon Kang, Samsung Bioepis Co., Ltd, 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea; dukwon72.kang{at}samsung.com
Citation
Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab)
Publication history
- Received August 16, 2016
- Revised December 6, 2016
- Accepted December 20, 2016
- First published January 13, 2017.
Online issue publication
April 25, 2018
Article Versions
- Previous version (13 January 2017).
- Previous version (27 March 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/